OMTRYG
Peakomega-3-acid ethyl esters type a
NDAORALCAPSULE
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OMTRYG (omega-3-acid ethyl esters type a) is understood. First approved in 2014.
Drug data last refreshed 1h ago · AI intelligence enriched 1h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMTRYG is an oral capsule containing omega-3-acid ethyl esters (EPA and DHA) approved in 2014 for triglyceride management. It works by inhibiting hepatic triglyceride synthesis, increasing fatty acid oxidation, and enhancing lipoprotein lipase activity. The mechanism leverages EPA and DHA as poor substrates for triglyceride-synthesizing enzymes while simultaneously inhibiting esterification of other fatty acids.
Peak
Product is at peak commercial stage with moderate competitive pressure (30%), suggesting stable revenue and established commercial team structure.
Mechanism of Action
understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal ß-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. Omega-3-acid ethyl esters may reduce…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OMTRYG positions you in a mature, stable commercial environment focused on defending market share against generic competition and newer therapeutic alternatives. Roles emphasize sales execution, payer relationships, and clinical messaging rather than launch-phase innovation.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.